Form 4: Neumora Therapeutics Director Maykin Ho Reports Option Repricing

Maykin Ho, a director at Neumora Therapeutics, reported the repricing of stock options on February 13, 2025, subject to stockholder approval.

Summary

• On February 13, 2025, Maykin Ho, a director of Neumora Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the repricing of several stock option grants.
• The exercise prices for these options were adjusted to $1.69 per share, contingent upon stockholder approval.
• The repricing affects options with original exercise prices of $2.51, $17, and $9.95.
• The repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option repricing. The sentiment is neutral as it simply reports a transaction.

Risks

• The option repricing is contingent on stockholder approval, and if this approval is not obtained, the original terms of the options will remain in effect.
• The repricing is also contingent on the director remaining in service through August 13, 2026; if the director leaves before this date, the repricing may be void.

Future Outlook

The repricing of the options is subject to stockholder approval, which will determine the final terms of the options.

Industry Context

Option repricing is a tool companies sometimes use to incentivize employees and board members, especially when the stock price has declined significantly since the original grant date. It aims to restore the incentive value of the options.

Stakeholder Impact

• The repricing of stock options could potentially impact shareholder value, depending on the company's future performance and the dilution effect of the options.
• The repricing is intended to incentivize the director, which could benefit the company if it leads to improved performance.

Next Steps

• The company needs to obtain stockholder approval for the option repricing.
• The director must remain in service through August 13, 2026, for the repricing to remain valid.

Key Dates